Cipla's #BerokZindagi Ushers in A New Era of Storytelling with Digital Content Platform FilterCopy
- Berok Zindagi resonates with audiences, accumulating 100 CR+ views across half a decade.
- Debuts 'A Monsoon Romance: When Opposites Attract' – A FilterCopy collab that hopes to enrich the narrative.
- Strengthens its mission: Empowering asthmatics to live an unstoppable life with new film; Berok Zindagi ke liye bas common sense he kaafi hai
MUMBAI, India, Sept. 13, 2023 /PRNewswire/ -- Cipla Ltd.'s #BerokZindagi, partners with one of India's leading digital entertainment companies, Pocket Aces, to create multiple sketches for the platform's leading short-form content channel - FilterCopy. By harnessing Pocket Aces' expertise in crafting and amplifying unique stories, Cipla hopes to further the mission of its largest public and patient awareness campaign - dispelling asthma myths, improving inhaler acceptance, and inspiring asthmatics to live a Berok Zindagi (unstoppable life). This partnership marks the pharmaceutical company's entry into alternative content formats, that uses relatable storytelling to convey and subtly reinforce an important message. The first video, 'A Monsoon Romance: When Opposites Attract', premiered today on FilterCopy's YouTube channel.
Link to Watch Cipla x FilterCopy Film: https://www.youtube.com/watch?v=4J8D-gC8GLc
Created in easy-to-consume, snackable and shareable formats, each video will tell a heartwarming 'Slice-of-life' story scripted by the creative team at FilterCopy in collaboration with Cipla. The first premiere is a captivating love story set against the backdrop of the romanticized Mumbai monsoons. It will not only endear audiences but will also shed light on the fact that monsoons can be triggers for asthmatics. However, through subtle character integrations, the film emphasizes that with proper doctor-prescribed treatment, even those with asthma can enjoy the rainy season to the fullest. All films will be cross amplified through FilterCopy's social media channels, reaching out to the 'Digital GECs' 22+ million audience and will be available in six languages – Hindi, Bengali, Telugu, Tamil, Malayalam, and Kannada.
Achin Gupta, CEO - One India Business, Cipla Ltd., said, "With India contributing almost 42% of global asthma deaths despite accounting for only 13% of the cases worldwide,[1] Asthma continues to be a high burden disease in India affecting both adults and children. Misconceptions about asthma and inhalers contribute to the imbalance in its prevalence and outcomes, but correcting these can significantly improve patients' lives. Over the years Cipla has pushed the boundaries with #BerokZindagi, employing a multitude of creative mediums to help combat misinformation, stigmas, and myths about asthma as well as inhalers and connect with today's audiences."
"By exploring various content formats that touch upon diverse themes our aim is to integrate our message of awareness and inspiration into the cultural fabric of the country, enabling us to reach and resonate with a wide-ranging audience. With this partnership, Berok Zindagi moves beyond being just an awareness campaign, but to a movement that aims to transform perceptions and improve the lives of those living with asthma."
Aditi Shrivastava, Co-Founder & CEO, Pocket Aces, said, "The Cipla partnership is very special especially since it aligns perfectly with our renewed mission of positive content at Pocket Aces. Storytelling can have a profound impact on dispelling misconceptions, as the Cipla team has already proved with innovative initiatives on their #BerokZindagi campaign. We have thoroughly enjoyed working with the team at Cipla to design content pieces that will address different communities and distinct use cases that will reach a massive audience. Via this campaign, we are looking forward to leveraging our channel FilterCopy to educate, break myths, and empower our audiences to live #BerokZindagi."
Using 'common sense' as a tool to convey its message, Asthma Ke Liye Inhalers Hain Sahi, Cipla also released an ad film that follows the story of a young schoolboy living with asthma. After being underestimated by the rival cricket team because of his condition, the young boy shows them up and defies expectations, showcasing his talent and determination in the sport, while also highlighting the importance of sticking to his treatment. With a digital first approach, the film is launched this week and features a new rendition of the popular #InhalersHainSahi song.
Link to Watch Film: Berok Zindagi ke liye bas common sense he kaafi hai ✅ - YouTube
[1] Mortimer, Kevin1,2; Salvi, Sundeep Santosh3,4; Reddel, Helen K.5,6,*. Closing gaps in asthma care in India – World Asthma Day 2022. Indian Journal of Medical Research 156(1):p 6-9, July 2022. | DOI: 10.4103/ijmr.ijmr_893_22
***
Disclaimer: This information is only for general awareness and is not to promote, use, or endorse any product or encourage use of medicines in any way nor implied to be a substitute for professional medical advice nor for diagnosis or treatment/ cure of any medical condition. The views expressed are independent opinion based on studies from authentic sources. Your discretion may be exercised before using the information for consulting doctor. Please consult your doctor/ Registered Medical Practitioner before starting any treatment/medicine/ inhaler. This is being used only as a reference to create awareness and is NOT intended towards advertising.
About Cipla:
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 86 markets. Cipla is the 3rd largest in pharma in India (IQVIA MAT November'22), 3rd largest in the pharma private market in South Africa (IQVIA MAT November'22) and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of "Caring for Life" and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders.
For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn
Photo: https://mma.prnewswire.com/media/2209665/Cipla_BerokZindagi.jpg
Logo: https://mma.prnewswire.com/media/2209680/Cipla_Logo.jpg
Share this article